PDF(Pubmed)
Abstract：
UNASSIGNED: This study aims to analyze giant ovarian tumors\' clinical and pathological characteristics.
UNASSIGNED: This was an analytical observational study. Medical records of all patients with giant ovarian tumors who underwent surgery between January 2020 and June 2022 at Dr. Soetomo Academic Hospital, Surabaya, Indonesia, were analyzed.
UNASSIGNED: We analyzed 63 patients with ovarian tumors measuring > 20 cm who underwent surgery at Dr. Soetomo Academic Hospital, Surabaya, Indonesia. The mean tumor size was 25.9 cm (largest size was 41 cm). There was no significant difference in tumor size between benign and malignant giant ovarian tumors (p = 0.261). Based on histopathological results, 66.67 % of giant ovarian tumors were malignant, 26.98 % were benign, and 6.35 % were borderline. Among the malignant tumors, the epithelial type accounted for 69 % of cases. Most giant ovarian tumors originated in the left adnexa (68.25 %). There was no significant difference in patient age (p = 0.511), tumor size (p = 0.168), malignancy (p = 0.303), and histopathological type (p = 0.232) regardless of adnexal side. CA125 levels did not differ significantly between malignant and benign giant ovarian tumors (p = 0.604). There was no correlation between malignant ovarian tumor size and CA125 levels, while there was a significant difference between CA125 levels and the adnexal side (p = 0.010).
UNASSIGNED: Most giant ovarian tumors were malignant, diagnosed at an early stage, and predominantly epithelial type. CA125 levels did not correlate with the size of malignant ovarian tumors. Most giant ovarian tumors originate in the left adnexa.
UNASSIGNED: This was an analytical observational study. Medical records of all patients with giant ovarian tumors who underwent surgery between January 2020 and June 2022 at Dr. Soetomo Academic Hospital, Surabaya, Indonesia, were analyzed.
UNASSIGNED: We analyzed 63 patients with ovarian tumors measuring > 20 cm who underwent surgery at Dr. Soetomo Academic Hospital, Surabaya, Indonesia. The mean tumor size was 25.9 cm (largest size was 41 cm). There was no significant difference in tumor size between benign and malignant giant ovarian tumors (p = 0.261). Based on histopathological results, 66.67 % of giant ovarian tumors were malignant, 26.98 % were benign, and 6.35 % were borderline. Among the malignant tumors, the epithelial type accounted for 69 % of cases. Most giant ovarian tumors originated in the left adnexa (68.25 %). There was no significant difference in patient age (p = 0.511), tumor size (p = 0.168), malignancy (p = 0.303), and histopathological type (p = 0.232) regardless of adnexal side. CA125 levels did not differ significantly between malignant and benign giant ovarian tumors (p = 0.604). There was no correlation between malignant ovarian tumor size and CA125 levels, while there was a significant difference between CA125 levels and the adnexal side (p = 0.010).
UNASSIGNED: Most giant ovarian tumors were malignant, diagnosed at an early stage, and predominantly epithelial type. CA125 levels did not correlate with the size of malignant ovarian tumors. Most giant ovarian tumors originate in the left adnexa.
摘要：
■本研究旨在分析巨大卵巢肿瘤的临床和病理特征。
■这是一项分析性观察研究。所有在2020年1月至2022年6月期间在Soetomo博士学术医院接受手术的巨大卵巢肿瘤患者的病历，泗水,印度尼西亚,进行了分析。
我们分析了在Soetomo博士学术医院接受手术的63例卵巢肿瘤>20厘米的患者，泗水,印度尼西亚。平均肿瘤大小为25.9cm（最大为41cm）。良性和恶性巨大卵巢肿瘤之间的肿瘤大小没有显着差异（p=0.261）。根据组织病理学结果,66.67%的巨大卵巢肿瘤为恶性,26.98%为良性，6.35%为临界。在恶性肿瘤中，上皮型占病例的69％。大多数巨大卵巢肿瘤起源于左附件(68.25%)。患者年龄差异无统计学意义(p=0.511),肿瘤大小（p=0.168），恶性肿瘤（p=0.303），和组织病理学类型（p=0.232），无论附件侧。恶性和良性巨大卵巢肿瘤之间的CA125水平没有显着差异（p=0.604）。卵巢恶性肿瘤大小与CA125水平无相关性,而CA125水平和附件侧之间存在显着差异（p=0.010）。
■大多数巨大卵巢肿瘤是恶性的，在早期诊断，以上皮型为主.CA125水平与恶性卵巢肿瘤的大小无关。大多数巨大卵巢肿瘤起源于左附件。
■这是一项分析性观察研究。所有在2020年1月至2022年6月期间在Soetomo博士学术医院接受手术的巨大卵巢肿瘤患者的病历，泗水,印度尼西亚,进行了分析。
我们分析了在Soetomo博士学术医院接受手术的63例卵巢肿瘤>20厘米的患者，泗水,印度尼西亚。平均肿瘤大小为25.9cm（最大为41cm）。良性和恶性巨大卵巢肿瘤之间的肿瘤大小没有显着差异（p=0.261）。根据组织病理学结果,66.67%的巨大卵巢肿瘤为恶性,26.98%为良性，6.35%为临界。在恶性肿瘤中，上皮型占病例的69％。大多数巨大卵巢肿瘤起源于左附件(68.25%)。患者年龄差异无统计学意义(p=0.511),肿瘤大小（p=0.168），恶性肿瘤（p=0.303），和组织病理学类型（p=0.232），无论附件侧。恶性和良性巨大卵巢肿瘤之间的CA125水平没有显着差异（p=0.604）。卵巢恶性肿瘤大小与CA125水平无相关性,而CA125水平和附件侧之间存在显着差异（p=0.010）。
■大多数巨大卵巢肿瘤是恶性的，在早期诊断，以上皮型为主.CA125水平与恶性卵巢肿瘤的大小无关。大多数巨大卵巢肿瘤起源于左附件。
